

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Matrix metalloproteinase 9 (MMP9)	Studies in mice suggest that antagonists of MMP9 could be combined with radiation for treating some cancers. In MMP9 knockout mice, tumors transplanted into preirradiated tissue were unable to grow and develop vasculature. However, secondary transplantation of MMP9-secreting bone marrow-derived CD11b ⁺ myelomonocytic cells restored tumor growth in the mice. Further research is necessary to test radiotherapy in combination with MMP9 inhibition as an antivasculogenic cancer therapy.	U.S. patent application filed by Stanford University; available for licensing	Ahn, G. & Brown, J. <i>Cancer Cell</i> ; published online March 12, 2008; doi:10.1016/j.ccr.2007.11.032 Contact: J. Martin Brown, Stanford University School of Medicine, Stanford, Calif. e-mail: mbrown@stanford.edu